| API Access | |

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Wakamoto Pharmaceutical Co., Ltd. Reports Q3

Source disclosure: February 04, 2026 WAKAMOTO PHARMACEUTICAL CO.,LTD. [4512.T] TOKYO, Feb 17 (Pulse News Wire) – Wakamoto Pharmaceutical Co., Ltd. (4512.T) reported consolidated results for Q3 FY2026 (ending March 2026). Revenue was ¥7.31 billion (+25.9% YoY). operating profit was ¥187 million. net profit was ¥215 million. Total assets stood at ¥15.8 billion with an equity ratio of 76.3%. The company declared an annual dividend of ¥3 per share. For the next fiscal year, the company

Source disclosure: February 04, 2026

WAKAMOTO PHARMACEUTICAL CO.,LTD. [4512.T]

TOKYO, Feb 17 (Pulse News Wire) – Wakamoto Pharmaceutical Co., Ltd. (4512.T) reported consolidated results for Q3 FY2026 (ending March 2026).

31 billion (+25.9% YoY).

8 billion with an equity ratio of 76.3%. For the next fiscal year, the company forecasts 0 billion (+28.4%).

Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.

AI-translated content. 🟢 Confidence: High See terms • Original filing

💬 Help us improve translation quality

Notice any errors in this article? Let us know with one click.

🎁 Report 3+ errors with your email and get a free month of premium access

Wakamoto Pharmaceutical Co., Ltd. Reports Q3

Related Disclosures